PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients

By HEOR Staff Writer

March 25, 2026

PEPFAR TB Impact has been profound, with the U.S. President’s Emergency Plan for AIDS Relief averting an estimated 11.0 million tuberculosis (TB) cases and 2.1 million TB-related deaths among persons with HIV between 2003 and 2024.

The PEPFAR TB impact extends far beyond HIV, delivering substantial collateral benefits for tuberculosis control in high-burden countries. The analysis published by NEJM shows that more than one-third (42%) of total TB cases averted occurred between 2020 and 2024, with the direct contribution of TB-specific interventions rising sharply from 18% in 2021 to 46% in 2024.

How the Impact Was Measured

The study used a negative binomial generalized linear mixed model to quantify PEPFAR’s contribution. Researchers created a composite intervention-exposure variable that captured both the intensity and cumulative duration of PEPFAR-supported HIV and TB activities at the country level, while adjusting for gross domestic product, total health expenditure, and population size.

Accelerating TB Prevention

Since 2018, the scale-up of universal symptom screening, expanded access to TB diagnostics, and preventive treatment for eligible persons with HIV has dramatically increased PEPFAR TB impact. These direct interventions have worked synergistically with long-standing HIV investments, accelerating progress against a disease that remains the leading cause of death among people with HIV worldwide.

Value for Global Health Financing

The 11.0 million TB cases and 2.1 million deaths averted demonstrate the exceptional return on investment of integrated HIV-TB programming. These findings provide compelling evidence for sustained donor and domestic financing, particularly as countries increase their own funding for health programs.

Reference url

Recent Posts

Vitamin B6 Depletion Risk in Carbidopa/Levodopa Therapy and Seizure Implications

By HEOR Staff Writer

Carbidopa/levodopa products used for Parkinson’s disease can cause vitamin B6 depletion risk, potentially leading to seizures. The U.S. Food and Drug Administration (FDA) has identified 14 cases of seizures linked to vitamin B6 deficiency, all occurring in patients taking levodopa doses above 1,0...
Advancing Collaborative TB Innovation to Tackle Drug Resistance

By João L. Carapinha

March 24, 2026

Collaborative TB Innovation is essential to ending the world’s deadliest infectious disease. Tuberculosis (TB) still claims millions of lives each year, with rising drug resistance, climate-driven migration, and conflict severely undermining global progress. While the burden falls heaviest on low...
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations

By João L. Carapinha

Medicare Drug Price Negotiations are increasingly relying on real-world evidence, according to a new citation analysis of the first drugs selected under the Inflation Reduction Act. The study examined how the Centers for Medicare and Medicaid Services (CMS) uses real-world evidence (RWE) in its M...